









Markets
/
Stocks
/
nasdaq-srzn
/

Surrozen Inc

SRZN

22.800USD

+1.550+7.29%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

195.42MMarket Cap

LossP/E TTM



Surrozen Inc

22.800

+1.550+7.29%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Surrozen Inc

Currency: USD Updated: 2026-02-06

Key Insights

Surrozen Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 72 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 42.00.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Surrozen Inc's Score

Industry at a Glance

Industry Ranking

72 / 392

Overall Ranking

192 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Surrozen Inc Highlights

StrengthsRisks

Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.65M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 10.65M.

Undervalued

The company’s latest PE is -1.30, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 7.28M shares, increasing 5.11% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 14.73K shares of this stock.

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

42.000

Target Price

+77.59%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Surrozen Inc is 5.71, ranking 334 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 983.00K, representing a year-over-year decrease of 90.17%, while its net profit experienced a year-over-year decrease of 4896.03%.

Score

Industry at a Glance

Previous score

5.71

Change



Financials

6.38

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.64

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Surrozen Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Surrozen Inc is 6.59, ranking 253 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.30, which is -79.83% below the recent high of -0.26 and -64.78% above the recent low of -2.14.

Score

Industry at a Glance

Previous score

6.59

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 72/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Surrozen Inc is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 37.00, with a high of 42.00 and a low of 32.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

42.000

Target Price

+77.59%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Surrozen Inc

SRZN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Surrozen Inc is 9.17, ranking 32 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 26.60 and the support level at 17.88, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.54

Change

1.63

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.351

Buy

RSI(14)

56.553

Neutral

STOCH(KDJ)(9,3,3)

56.857

Sell

ATR(14)

2.461

Low Volatility

CCI(14)

46.957

Neutral

Williams %R

35.648

Buy

TRIX(12,20)

0.424

Sell

StochRSI(14)

48.696

Neutral

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

22.576

Buy

MA10

22.154

Buy

MA20

20.771

Buy

MA50

20.598

Buy

MA100

16.816

Buy

MA200

13.187

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Surrozen Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 84.95%, representing a quarter-over-quarter increase of 18.27%. The largest institutional shareholder is The Vanguard, holding a total of 319.24K shares, representing 3.72% of shares outstanding, with 363.35% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Column Group LP

1.85M

+1.99%

StemPoint Capital LP

713.46K

+3.92%

VR Adviser, LLC

632.93K

RA Capital Management, LP

602.63K

Millennium Management LLC

564.85K

+414.58%

The Vanguard Group, Inc.

Star Investors

266.42K

+21.68%

5AM Ventures

310.00K

Access Industries, Inc.

306.00K

Vivo Capital, LLC

260.00K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Surrozen Inc is 2.53, ranking 223 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.59. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.